{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Juvenile+Idiopathic+Arthritis&page=2", "query": { "condition": "Systemic Juvenile Idiopathic Arthritis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Systemic+Juvenile+Idiopathic+Arthritis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T20:38:08.916Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT00642460", "title": "A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Non-steroidal anti-inflammatory drugs (NSAIDs)", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 112, "start_date": "2008-05", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 13, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642460" }, { "nct_id": "NCT02296424", "title": "ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis (SJIA)" ], "interventions": [ { "name": "ACZ885 150 mg (Canakinumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 182, "start_date": "2014-11-17", "completion_date": "2017-09-25", "has_results": true, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 2, "location_summary": "Los Angeles, California • Columbus, Ohio", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296424" }, { "nct_id": "NCT01697254", "title": "The CARRA Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Juvenile Idiopathic Arthritis", "Systemic Lupus Erythematosus", "Mixed Connective Tissue Disease", "Juvenile Ankylosing Spondylitis", "Juvenile Dermatomyositis", "Localized Scleroderma", "Systemic Sclerosis", "Vasculitis", "Sarcoid", "Fibromyalgia, Primary", "Auto-inflammatory Disease", "Idiopathic Uveitis Idiopathic" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9587, "start_date": "2009-08", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01697254" }, { "nct_id": "NCT05000216", "title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis (RA)", "Systemic Lupus Erythematosus (SLE)", "Pemphigus Vulgaris", "Multiple Sclerosis (MS)", "Systemic Sclerosis (SSc)", "Pediatric SLE", "Juvenile Idiopathic Arthritis (JIA)", "Juvenile Dermatomyositis (JDM)", "Pediatric-Onset Multiple Sclerosis (POMS)" ], "interventions": [ { "name": "Moderna mRNA-1273", "type": "BIOLOGICAL" }, { "name": "BNT162b2", "type": "BIOLOGICAL" }, { "name": "Ad26.COV2.S", "type": "BIOLOGICAL" }, { "name": "Continue IS (MMF or MPA)", "type": "DRUG" }, { "name": "Continue IS (MTX)", "type": "DRUG" }, { "name": "Continue IS (B cell depletion therapy)", "type": "BIOLOGICAL" }, { "name": "Monovalent [B.1.351] CoV2 preS dTM-AS03", "type": "BIOLOGICAL" }, { "name": "Withhold IS (MMF or MPA)", "type": "DRUG" }, { "name": "Withhold IS (MTX)", "type": "DRUG" }, { "name": "Withhold IS (B cell depletion therapy)", "type": "DRUG" }, { "name": "Moderna mRNA-1273, Bivalent", "type": "BIOLOGICAL" }, { "name": "BNT162b2, Bivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 258, "start_date": "2021-08-13", "completion_date": "2024-03-28", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 29, "location_summary": "Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05000216" }, { "nct_id": "NCT06556992", "title": "Fitness Integrative Training for Pediatric Rheumatology Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Juvenile Idiopathic Arthritis", "Systemic Lupus Erythematosus of Childhood", "Joint Hypermobility", "Juvenile Dermatomyositis" ], "interventions": [ { "name": "FIT Teens", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "10 Years to 19 Years" }, "enrollment_count": 10, "start_date": "2024-09-24", "completion_date": "2025-07-02", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06556992" }, { "nct_id": "NCT01962415", "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Immunodeficiency (PID)", "Congenital Bone Marrow Failure Syndromes", "Inherited Metabolic Disorders (IMD)", "Hereditary Anemias", "Inflammatory Conditions", "Systemic Juvenile Idiopathic Arthritis (sJIA)", "Juvenile Rheumatoid Arthritis (JRA)" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Months to 55 Years" }, "enrollment_count": 100, "start_date": "2014-02-04", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01962415" }, { "nct_id": "NCT05609630", "title": "Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 90, "start_date": "2023-10-02", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609630" }, { "nct_id": "NCT03265132", "title": "A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Still's Disease, Adult-Onset", "Still's Disease, Juvenile-Onset" ], "interventions": [ { "name": "anakinra", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Swedish Orphan Biovitrum", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 13, "start_date": "2017-09-26", "completion_date": "2019-05-23", "has_results": true, "last_update_posted_date": "2021-06-30", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03265132" }, { "nct_id": "NCT00886769", "title": "Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "2 Years to 19 Years" }, "enrollment_count": 84, "start_date": "2009-07", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-06-10T20:38:08.916Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00886769" } ] }